Cargando…
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
BACKGROUND: Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), the lifetime cost-effectiveness of three major treatments (radical radiotherapy, radical prostatectomy and active...
Autores principales: | Sanghera, S., Mohiuddin, S., Coast, J., Garfield, K., Noble, S., Metcalfe, C., Lane, J. A., Turner, E. L., Neal, D., Hamdy, F. C., Martin, R. M., Donovan, J. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542698/ https://www.ncbi.nlm.nih.gov/pubmed/33028256 http://dx.doi.org/10.1186/s12885-020-07276-4 |
Ejemplares similares
-
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011) -
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022) -
Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015) -
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
por: Noble, Sian M., et al.
Publicado: (2020) -
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)